Literature DB >> 11140242

Tacrolimus in acute renal failure: does L-arginine-infusion prevent changes in renal hemodynamics?

K Lopau1, D Kleinert, J Erler, L Schramm, E Heidbreder, C Wanner.   

Abstract

Nephrotoxicity is one of the main side effects of calcineurin-inhibitors. The influence of tacrolimus on the renal vasculature has not been well described. We have therefore examined the effects of tacrolimus on renal functional parameters as well as the contribution of the NO-system in a model of ischemic acute renal failure (ARF). Induction of ARF was achieved by clamping both renal arteries of female Sprague-Dawley rats. During the experiment, RBF, GFR, MAP, RVR and FENa were determined during infusion of vehicle, TAC, TAC and the NOS-activator L-arginine, and TAC and NOS-inhibition due to L-NMMA. TAC induced a significant rise in RVR with further decrease of RBF and GFR. Simultaneous L-arginine-infusion could reverse these effects during the infusion without complete restoration to preischemic levels. NOS-inhibition increased MAP and RBF without any effect on GFR. FENa did not differ significantly between the groups. Tacrolimus in the situation of ischemic acute renal failure causes vasoconstriction of pre- and postglomerular vessels with a further deterioration of renal function. L-arginine abolishes the functional deterioration, most likely due to increased NO-liberation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11140242     DOI: 10.1007/s001470050726

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  2 in total

Review 1.  Organ systems dependent on nitric oxide and the potential for nitric oxide-targeted therapies in related diseases.

Authors:  Norman K Hollenberg
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

2.  Volume management in the critically ill patient with acute kidney injury.

Authors:  Mary Labib; Raeesa Khalid; Akram Khan; Supriya Khan
Journal:  Crit Care Res Pract       Date:  2013-02-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.